In contrast, ACC-II is a more indolent subtype driven by TP63 and receptor tyrosine kinase activation (e.g., EGFR, MET) along with their downstream pathways, and is associated with a favorable long-term prognosis. The gene discussed is MET; the disease is adrenal cortex carcinoma.